HBQ1

Across TCGA pan-cancer cohorts, HBQ1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of HBQ1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where HBQ1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types HBQ1 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where HBQ1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HBQ1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+1.212	<.001	11	view →
HNSC	Male	III,IV	−1.077	<.001	11	view →
LSCC	Male	II,III,IV	−2.047	<.001	9	view →
LUAD	Female	III,IV	−1.898	<.001	9	view →
OV	All	All	−1.639	<.001	2	view →
PDAC	All	III,IV	−1.177	.014	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

HBQ1–CCRCC

Open the CCRCC breakdown →